Boryung Pharmaceutical and VigenCell Sign Joint Investment and Exclusive Sales Agreement for Lymphoma Treatment

[Asia Economy Reporter Cho Hyun-ui] Boryung Pharmaceutical announced on the 11th that it has signed a joint investment and exclusive sales agreement with VigenCell for the NK/T-cell lymphoma treatment ‘VT-EBV’.

Through this agreement, Boryung Pharmaceutical will hold exclusive domestic sales rights for VT-EBV’s NK/T-cell lymphoma indication for 10 years, and if additional indications are added in the future, it will have the right of first negotiation for exclusive sales rights for those indications.

VT-EBV demonstrated an overall survival rate of 100% and a relapse-free survival rate of 90% in a researcher-initiated Phase 1 clinical trial where 10 NK/T lymphoma patients were administered a total of 8 doses and observed for over 5 years. It entered Phase 2 clinical trials in April last year and was designated as an orphan drug in the development stage in October of the same year. VigenCell plans to apply for conditional product approval after completing Phase 2 and proceed with commercialization.

Ahn Jae-hyun, CEO of Boryung Pharmaceutical, said, "We will be able to further enhance synergy through joint development and marketing," adding, "Expanding our portfolio to include immune cell therapies with excellent platform technology will also strengthen our global expansion efforts."

This content was produced with the assistance of AI translation services.